What is the Genohco Inc. stock price forecast?

Genohco Inc. is currently trading at ₩16,730. View real-time AI analysis on Alpha Lenz.

What is Genohco Inc. insider trading activity?

View the latest insider trading data for Genohco Inc. on Alpha Lenz.

What is Genohco Inc.'s P/E ratio?

Genohco Inc.'s P/E ratio is -76.8.

Genohco Inc.

KRX · 361390

₩16,730-640(-3.68%)Market closed

Ask about Genohco Inc.'s future dividend policy...

Alpha Chat Insight

“Genohco Inc. trades at a P/E of -76.8 (undervalued) with modest ROE of -4.9%.”

Ask for details →

Company Overview

Genohco Inc. is a global biotechnology company specializing in the development of innovative therapies and pharmaceuticals. The primary focus of Genohco Inc. is to advance treatments that address unmet medical needs in areas such as oncology, neurology, and rare diseases. Notable for its robust research and development pipeline, Genohco Inc. leverages cutting-edge technologies like CRISPR and monoclonal antibodies to bring novel solutions to the healthcare industry. The company plays a crucial role in the biotech sector, collaborating with academic institutions and various healthcare entities to accelerate scientific discovery and improve patient outcomes. Headquartered in a key biotech hub, Genohco Inc. continues to expand its presence through strategic partnerships, acquisitions, and advancements in precision medicine.

CEO유태삼

Websitehttps://www.genohco.com

SectorTechnology

IndustryCommunication Equipment

Company Statistics

FY 2025

Profile

₩162,889,654,130Market Cap

₩59,631,313,380Revenue

9.74MShares Out

0Employees

Margins

4.17%Gross

0.43%EBITDA

-3.50%Operating

-4.50%Pre-Tax

-3.56%Net

Valuation

-76.82P/E

3.15P/B

2.73EV/Sales

590.57EV/EBITDA

-7.70P/FCF

Growth (CAGR)

5.55%Rev 3Yr

11.83%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-2.42%ROA

-4.93%ROE

-1.53%ROIC

Financial Health

₩29,595,673,240Cash & Cash Equivalents

₩6,261,007,410Net Debt

69.25%Debt/Equity

N/AInterest Cov